Aphria Inc. Is Uglifying Itself With Absurdly Expensive Acquisitions

Aphria Inc. (TSX:APH) may be shooting itself in the foot with these recent acquisitions.

| More on:

The cannabis market in general is a very dangerous place to be right now. Last year, pot stocks were driven by political developments, supply deals, and partnerships with foreign firms, but now pot stocks are being propelled higher by M&A activity, as the bigger producers look to consolidate the industry to prepare for years of what many believe is overwhelming demand for legal cannabis.

There are still a tonne of unforeseen obstacles that could stand in the way of Canada’s top cannabis producers, and at current valuations, I’d advise investors take a rain-check and come back after a 50-60% correction, which I think is extremely probable this year.

Aphria Inc. (TSX:APH) is my least favourite Canadian cannabis stock for many reasons. Despite possessing the most efficient operations and the best fundamentals in its industry, there are a lot of other insidious traits that I believe will haunt investors who fail to look past the “incredible fundamentals” at the very early stages of an emerging industry.

First, Aphria has U.S. assets, which could affect its ability to trade on the TSX. That is, of course, until the company decides to dispose of its U.S. assets before some unknown deadline, which may or may not exist at this point in time.

What are the implications of a delisting?

Nobody knows, but CEO Vic Neufeld has downplayed the matter, which I think is a cause for concern, especially since he may be putting investors at risk from the severe lack of transparency. At this point, Neufeld may be favouring the divestment of the U.S. assets; however, I think it’ll be a tough sell, especially given Aphria’s vulnerable position. It’s clear that the buyer will have most, if not all, of the bargaining power should a deal be made, and that’s bad news for Aphria shareholders.

Fellow Fool contributor Will Ashworth noted that Aphria may be better off ditching the TSX for an alternative exchange like Canadian Securities Exchange, where there are ample marijuana firms. This may be a better move, but I doubt this is will be the route it’ll end up taking.

Second, Aphria has been wheeling and dealing a lot lately at a time when many analysts and Fools, including me, believe that the entire cannabis market is in a bubble. In a previous piece, I mentioned my distaste for Aphria’s Broken Coast acquisition for $230 million, and Nuuvera Inc. was scooped up just a few weeks later for $826 million.

Nuuvera is a great grower that provides Aphria exposure to Europe, Africa, and the Middle East, but the 21% premium that was paid makes me cringe, and it brings back memories of Valeant Pharmaceuticals Intl Inc. and its greed-fueled acquisition spree.

The recent deal makes it look like Aphria is making moves to “keep up with the Joneses,” where Aurora Cannabis Inc. (TSX:ACB) is Mr. and Mrs. Jones. Aphria’s Nuuvera deal was announced just days after Aurora’s $1.1 billion acquisition of CanniMed Therapeutics Inc.

Clearly, the market is valuing these smaller cannabis firms ridiculously high, but I suspect they won’t be worth nearly as much as we head into the latter part of the year. Aurora’s CanniMed deal severely dilute shareholders, and I fear this could be just the start of further deals that will dilute shareholders to death.

Bottom line

There are a tonne of differences between Aurora and Aphria versus Valeant (like differing debt levels). But one thing they have in common is the trigger-happy nature of acquisitions, which could be coming at a fast and furious rate over the next few months. I personally believe such deals may be sacrificing long-term shareholder value in favour of shorter-term results.

Stay hungry. Stay Foolish.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Joey Frenette has no position in any of the stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

stock analysis
Dividend Stocks

Buy These TSX Dividend Shares Next Week

Are you looking for dividend stocks to add to your portfolio? Buy these picks next week!

Read more »

Shopping and e-commerce
Tech Stocks

1 Tech Stock You’ll Be Glad You Bought When the Bull Market Starts

Historically, tech stocks have done well during bull markets. Here’s one you’ll be happy you bought before the next bull…

Read more »

edit Safety First illustration
Dividend Stocks

3 of the Safest Dividend Stocks in Canada

These three dividend stocks are all high-quality companies with defensive operations, making them some of the safest investments in Canada.

Read more »

data analyze research
Bank Stocks

Better Buy: Royal Bank Stock or Bank of Nova Scotia?

Bank stocks appear cheap after the latest plunge. Is Royal Bank or Bank of Nova Scotia a buy today?

Read more »

A person builds a rock tower on a beach.
Dividend Stocks

3 Stocks to Anchor Your Portfolio in a Rocky Market

Three stocks are solid anchors in any portfolio today for their outperformance in a weak market and defiance of the…

Read more »

Metals and Mining Stocks

Better Metals Buy: Gold Stocks vs. Lithium Stocks

Gold is the evergreen choice as a hedge against inflation and weak markets. In contrast, battery metals may offer unique…

Read more »

Man making notes on graphs and charts
Bank Stocks

TD Bank Stock: A TSX Top Pick Amid U.S. Banking Rout?

TD Bank (TSX:TD) stock could prove a worthy bet for brave investors who aren't fearful over the recent wave of…

Read more »

edit Sale sign, value, discount
Tech Stocks

2 Cheap Tech Stocks to Buy Right Now

Many tech stocks offer exceptional returns compared to other stock sectors when the market is bullish. You can add to…

Read more »